Amylin receptor agonist: difference between revisions
Diff·revision 8 → 9·17:02, 29 Dec 2024
Difference between revision 8 and revision 9 of Amylin receptor agonist. 5 lines changed; the page grew by 600 bytes.
| Revision 8 — 21:40, 12 Dec 2024 TechnicianTeal (talk) add the receptor targets to the lead sentence 2,905 bytes ±0 | Revision 9 — 17:02, 29 Dec 2024 StubSorterBot (talk) bot: expand DOI to full citation 3,505 bytes +600 | ||
|---|---|---|---|
| 19 | Cagrilintide adds acylation for [[Albumin binding half-life extension|albumin binding]], reaching a half-life supporting weekly administration. It engages the calcitonin receptor as well as the amylin receptors, and whether that broader engagement contributes to or detracts from the clinical effect is not established.{{r|lau2021}} | 19 | Cagrilintide adds acylation for [[Albumin binding half-life extension|albumin binding]], reaching a half-life supporting weekly administration. It engages the calcitonin receptor as well as the amylin receptors, and whether that broader engagement contributes to or detracts from the clinical effect is not established.{{r|lau2021}} |
| 20 | 20 | ||
| + | 21 | == Clinical findings == | |
| + | 22 | Pramlintide reduces postprandial glucose excursions in insulin-treated diabetes and produces modest weight reduction, on the order of 1–2 kg. Its adoption was limited by mealtime dosing, a separate injection from insulin, and hypoglycaemia when insulin doses were not reduced at initiation.{{r|hay2015}} | |
| + | 23 | ||
| + | 24 | Cagrilintide monotherapy produced approximately 10% weight reduction at 26 weeks in a phase 2 trial. In combination with semaglutide, reported weight reduction exceeds that of either component alone; the combination programme is covered at [[CagriSema]].{{r|lau2021}} | |
| + | 25 | ||
| 21 | == References == | 26 | == References == |
| 22 | {{reflist}} | 27 | {{reflist}} |